Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1682 details
Primary information
ThPP IDTh1163
Therapeutic Peptide/Protein NameAncestim
SequenceNA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight18500
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionAncestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008. It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor. It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients
Indication/DiseaseIndicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients
PharmacodynamicsNA
Mechanism of ActionRecombinant human stem cell factor
ToxicityNA
MetabolismWhen radiolabelled ancestim was administered to rats, 90% of the radioactivity was excreted in the urine. Ancestim was not quantifiable in rat urine using Enzyme-Linked Immunosorbent Assay (ELISA), indicating degradation to lower molecular weight products prior to excretion.
Absorption35-41 hr
Volume of DistributionNA
ClearanceApparent clearance (CL/F) is approximately 35 to 40 mL/hour/kg.
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameStemgen
CompanyBiovitrum Ab (publ)
Brand DiscriptionAncestim/Water
Prescribed forindicated for use in combination with NEUPOGEN® (filgrastim) in the setting of autologous peripheral blood progenitor cell (PBPC) transplantation for patients at risk of poor PBPC mobilisation to increase the number of PBPC collected in the apheresis harvest, thereby increasing the proportion of patients reaching a PBPC target for transplantation.
Chemical NameNA
FormulationReconstitute with 1.2 mL sterlie water for injection to yield a concentration of 1.5 mg/mL with a withdrawable volume of 1 mL. Compatibility with saline or other diluents is unknown. During reconstitution, the vial contents may be gently swirled to avoid foaming during dissolution. Avoid excess or vigorous agitation
Physcial AppearnceNA
Route of AdministrationSubcutaneous
Recommended Dosage20 mcg/kg/day SC
ContraindicationIt is contraindicated in patients with known hypersensitivity to E coli-derived proteins, ancestim or any component of the product; increased risk of systemic allergic reactions (greater incidence and severity) when STEMGEN® was administered by the IV route
Side EffectsInjection site reactions (92%); Paresthesia (29%); Respiratory symptoms (28%); Distant skin reactions (21%);Nausea (16%); Headache (13%); Dizziness (12%); Tachycardia (8%)
Useful Linkhttp://reference.medscape.com/drug/stemgen-ancestim-342267; http://www.medicines.org.au/files/anpstemi.pdf
PubMed IDUS20080112953
3-D StructureN.A.